- 1 The Pattern of rpoB gene mutation of Mycobacterium tuberculosis and predictors of
- 2 rifampicin resistance detected by gene Xpert MTB/Rif in Tanzania.

3 Authors

- 4 Peter Richard Torokaa^{1,2*}, Heledy Kileo³, Loveness Urio², Mariam R. Mbwana^{1,2} Mariam C.
- 5 Monah^{1,2}, Sephord Saul Ntibabara^{1,2}, Jasper Kimambo^{1,2}, Paschal Seleman³, Collins Franklin³,
- 6 Robert Balama³, Riziki M. Kisonga³, Mtebe V. Majigo⁴, Agricola Joachim⁴

7 Affiliations

- 8 ¹Muhimbili University of Health and Allied Sciences, School of Public Health and Social Sciences,
- 9 Dar es Salaam, Tanzania.
- ²Tanzania Field Epidemiology and Laboratory Training Program, Dar es Salaam, Tanzania.
- ³Ministry of Health, National TB and Leprosy Program, Dodoma Tanzania.
- ⁴Muhimbili University of Health and Allied Sciences, College of Medicine, Dar es Salaam,
- 13 Tanzania

16

*Corresponding Author: Peter Torokaa, Email: <u>petertorokaa@gmail.com</u> (PRT)

15 ABSTRACT

Introduction

- 17 Antimicrobial resistance associated with *Mycobacterium tuberculosis (MTB)* is the challenge
- facing Tuberculosis (TB) management worldwide. Rifampicin resistance (RR) has been associated
- with the rpoB gene mutation. No study was conducted in Tanzania to determine the commonest
- 20 mutation. The inconsistent findings from various studies support the need to determine whether

- 21 reported mutation patterns are applicable in our setting. We determined the frequency of rpoB gene
- mutation and factors associated with RR detected using GeneXpert MTB/Rif.

Methods

23

- We conducted a retrospective cross-sectional study involving data from the National Tuberculosis
- and Leprosy Program database from 2020 to 2022 for cases investigated using GeneXpert.
- Descriptive analysis was performed as the frequency for categorical variables. The chi-square test
- and regression analysis assessed the relationship between the independent variables and outcome.
- The 95% confidence interval and a significance level of p<0.05 were used to assess the association
- 29 strength.

30

39

Results

- A total of 56,004 participants had status of MTB and RR. Most, 38,705/56,004 (69.11%) were male.
- Probe E, 89/219 (40.64%) was the predominant. Human immunodeficiency virus (HIV)-positive
- patients had a higher gene mutation, 134/10601 (1.26%) than HIV-negative, 306/45016 (0.68%)
- 34 (p<0.001). Patients with both pulmonary and extra-pulmonary TB had about four times greater odds
- of developing rifampicin resistance (AOR 3.88, 95%CI: 1.80 8.32). RR was nearly nine times
- 36 higher in previously treated patients than new patients (AOR 8.66, 95%CI: 6.97–10.76). HIV-
- 37 positive individuals had nearly twice the odds of developing RR than HIV-negative individuals
- 38 (AOR 1.91, 95%CI: 1.51 2.42).

Conclusion

- 40 The rate of RR was low compared to other studies in Tanzania, with probe E mutations the most
- 41 prevalent. Patients with disseminated TB, HIV co-infection and those with prior exposure to anti-

- 42 TB had more risk of RR. The findings highlight the need to strengthen surveillance of multidrug-
- resistant-TB among patients with a higher risk of RR.
- **Keywords:** *Mycobacterium tuberculosis*, rifampicin resistance, GeneXpert, probe mutations,
- 45 Tanzania

46

Introduction

- 47 Multidrug-resistant Mycobacterium tuberculosis (MDR-TB) is the biggest challenge facing
- Tuberculosis (TB) care and treatment worldwide (1). MDR-TB is a major contributor to global
- antimicrobial resistance (AMR) and continues to pose a public health threat (1–3). MDR-TB is
- 50 considered when there is resistance to isoniazid and rifampicin, with or without resistance to other
- 51 first-line drugs. The main problem is rifampicin resistance, the most potent first-line treatment (1).
- Patients with rifampicin-resistant TB or MDR-TB require a second-line treatment regimen (4).
- Globally, the annual estimated number of MDR-TB or rifampicin-resistant TB cases was steady
- between 2015 and 2020; however, it increased in 2021. In 2021, it was estimated to be 450,000
- events, a 3.1% increase from 437,000 in 2020 (1).
- The World Health Organization (WHO) developed a strategy to end TB-related deaths, illnesses,
- and suffering by 2035 (5). It recommends accelerating the identification and enhancing treatment
- for MDR-TB. Apart from access to diagnosis, adequate infection control must also be implemented
- in the settings where patients are treated (4). To diagnose MDR-TB, WHO recommends more
- specific and sensitive assays like real-time polymerase chain reaction (RT-PCR), DNA microarray,
- and loop-mediated isothermal amplification (LAMP). These technologies determine the mutations
- 62 in the genes to identify drug resistance. In some populations of HIV-infected presumptive TB

patients, the lateral flow lipoarabinomannan assay (LF-LAM) test is advised to aid in the diagnosis 63 of TB (6). 64 65 The invention of the Xpert® MTB/RIF Assay (Cepheid, USA), which simultaneously detects the presence of Mycobacterium tuberculosis (MTB) and rifampicin resistance, has transformed the 66 diagnosis of TB. Rifampicin inhibits DNA-directed RNA synthesis of MTB proteins by binding to 67 68 the subunit of the bacterial DNA-dependent RNA polymerase (rpoB) enzyme. Rifampicin resistance has been associated with the rpoB gene mutation. Almost 96.1% of rifampicin-resistant 69 70 MTB strains have *rpoB* mutations (7). The rifampicin resistance is the proxy sign of the MDR-TB (8,9). GeneXpert/MTB RIF is a cartridge-based, automated hemi-nested-nested real-time 71 Polymerase Chain Reaction (PCR) system that utilizes five overlapping probes named Probe A 72 (codons 507–511), Probe B (codons 511–518), Probe C (codons 518–523), Probe D (codons 523– 73 529) and Probe E (codons 529–533) (10). 74 Studies in Africa revealed that the commonest mutation of rooB occurs at probes E and D (11–13). 75 76 However, the literature shows different pattern distributions of the rpoB gene mutation of MTB associated with drug resistance (11–13). There is a need to determine whether the findings in other 77 studies apply to our setting due to the varied findings obtained in various geographical areas. No 78 other study has been conducted in Tanzania to reveal the patterns of rpoB mutation. Due to efforts 79 to increase access to GeneXpert MTB/RIF diagnosis in the country, there is also a need to determine 80

Methods

81

82

83

Study design and setting

the factors associated with Rifampicin-resistant TB.

We conducted a retrospective cross-sectional study involving the Tanzania National Tuberculosis and Leprosy Program (NTLP) data collected from January 2020 through December 2022. The study covered Presumptive TB cases notified to NTLP from 26 regions of Tanzania's mainland. The NTLP is tasked with preventing tuberculosis and leprosy as serious public health concerns in Tanzania, and it was launched in 1977 as a single combined programme for the two diseases.

Data collection

We extracted demographic and clinical data from eTL and laboratory results from gxalert databases on 10th October, 2023 and then exported them to Microsoft Excel. The demographic data from the eTL register and laboratory results data were linked between these two databases. The identifiers used to link the two databases were patient name, health facilities, district, and year. The variables of interest from the two databases were demographic characteristics (age, gender, residence), clinical characteristics (TB treatment history, type of TB, bacillary load, HIV status), and geneXpert results.

Data analysis

We presented the descriptive analysis with frequency distributions (%) for categorical variables and a mean was a measure of central tendency for age. Regression analyses (bivariate and multivariate) were performed to assess the relationship between demographic and clinical characteristics as independent variables and the rifampicin resistance as an outcome variable. Factors with a p-value of 0.20 in the bivariate analyses were included in the multivariable model using forward selection. The 95% confidence interval (CI) was presented, and a significance level of p <0.05 was used.

Results

We extracted data for 112,768 nonrepeating patients tested for TB using GeneXpert. Of all, 56,662 (50.2%) had laboratory-confirmed TB. Rifampicin resistance was identified in 450/56,662 (0.8%) patients with MTB. The specific gene mutations in the rpoB gene of *Mycobacterium tuberculosis* were identified in the form of the missing probes, which indicated a specific mutation occurs at a specific codon in the rpoB gene named Probe A (codons 507–511), Probe B (codons 511–518), Probe C (codons 518–523), Probe D (codons 523–529), and Probe E (codons 529–533). Missing probes (specific rpoB mutation detected) were found in 219/450 (48.7%) samples with Rifampicinresistant MTB, and no missing probes (no specific rpoB mutation detected) in 231/450 (51.3%) with Rifampicin-resistant. Rif Indeterminate were observed in 658/56,662 (1.16%) of patients with MTB and were excluded in further analysis (Fig 1).

Fig 1. Flow chart of participants' analysis

Demographic and clinical characteristics of study participants

A total of 56,004 participants had clear status of MTB and rifampicin resistance. Most of them, 38,705/56,004 (69.11%) were male. The age group 35- 44 years accounted for the largest cases, 13,512/56,004 (24.13%). Most participants, 55,192/56,004 (98.55%), had pulmonary TB. Participants with new TB were 53,818/56,004 (96.1%), and 45,016/56,004 (80.38%) were HIV-negative (Table 1). The Dar es Salaam region contributed 10,524/56,004 (18.79%) cases, which is higher than in any other region. The lowest number of cases were reported from the Katavi region. The regional distribution of cases is shown in Fig 2.

Table 1. Participants' demographic and clinical characteristics (N=56,004)

Variable	Frequency	Percent (%)
Age Group (years)		
<15	1765	3.15

Variable	Frequency	Percent (%)	
15-24	6441	11.5	
25-34	12637	22.56	
35-44	13512	24.13	
45-54	10460	18.68	
>55	11189	19.98	
Mean age (SD)	41(16.4)		
Gender			
Male	38705	69.11	
Female	17299	30.89	
TB Type			
Pulmonary	55192	98.55	
Extra pulmonary	550	0.98	
Pulmonary and extra pulmonary	262	0.47	
Treatment History			
New patient	53818	96.1	
Previous treated	2186	3.9	
HIV status			
Positive	10601	18.93	
Negative	45016	80.38	
Unknown	387	0.69	

Fig 2. Map showing the proportion distribution of study participants per region

Pattern of specific rpoB gene mutations in MTB

126

127

128

129

130

131

132

133

134

135

Specific mutations (missing probe) were detected in 219/450 (48.7%) rifampicin-resistant TB. The most prevalent mutation, 89/219 (40.64%), occurred at Probe E, followed by Probe D, 44/219 (20.09%), and the least mutation, 10/219 (4.56%), occurred at Probe C. We found a mutation combination of Probe A and B, 5/219 (2.28%), Probe A and D, 2/219 (0.91%), Probe A and E 1/219 (0.46%), and Probe B and E 1/219 (0.46%). One patient had a triple mutation combination at Probe A, D, and E 1/219 (0.46%) (Table 2).

Table 2. Frequency and distribution of specific rpoB gene mutations (N=219)

Probes	#Codons	#Codons Frequency	
Probe A	507–511	21	9.59
Probe B	511–518	39	17.81
Probe C	518–523	10	4.57
Probe D	523–529	44	20.09
Probe E	529–533	89	40.64
Probe A+B		5	2.28
Probe A+D		2	0.91
Probe A+E		1	0.46
Probe B+E		1	0.46
Probe A+D+E		1	0.46

The proportion of participants with no missing probe

Specific rpoB mutation were not detected (no missing probe) in 231/450 (51.3%) participants with Rifampicin-resistance. We found that no missing probes were significantly higher in new TB patients, 189/334 (56.59%) compared to previously treated patients, 42/116(36.21%) (p = 0.003). Patients with a very low TB bacillary load, 199/263 (75.67%), had a higher number of no missing probes when compared with other categories (p<0.001). There was no statistically significant difference of no missing probes for other variables (Table 3).

Table 3. Demographic and Clinical characteristics of the number of no-missing probe study participants (N=450)

Variable	Total	# No missing probe	Proportion	P value
	Rifampicin			
	Resistant			
Age Group				
<15	6	3	50.00	
15-59	376	185	49.20	
>59	68	43	63.24	0.103
Gender				

Variable	Total	# No missing probe	Proportion	P value
	Rifampicin		-	
	Resistant			
Male	312	168	53.85	
Female	138	63	45.65	0.133
TB Type				
Pulmonary	438	224	51.14	
Extra pulmonary	5	2	40.00	
Pulmonary and extra pulmonary	7	5	71.43	0.59
Treatment History				
New patient	334	189	56.59	
Previous treated	116	42	36.21	0.003
HIV status				
Positive	134	59	44.03	
Negative	306	167	54.58	0.12
Bacillary Load				
High	61	10	16.39	
Medium	66	5	7.58	
Low	60	17	28.33	
Very low	263	199	75.67	< 0.001

Rifampicin resistance and participant characteristics

GeneXpert detects the mutation in the rpoB mutations, and the final results are provided as rifampicin-resistant. The rpoB gene mutation was higher in 15-59-year-old patients, 383/45,782 (0.84%) compared to other age groups (p = 0.047). More mutations were found in patients with pulmonary and extra-pulmonary TB patients (7/262, 2.67%) than in pulmonary or extra-pulmonary alone (p = 0.003). Furthermore, we found that previously treated patients had a higher mutation rate, 116/2186 (5.31%), compared to new patients (p<0.001). HIV-positive TB patients had a higher gene mutation, 134/10601 (1.26%), than HIV-negative, 306/45016(0.68%) (p<0.001). Other variables like gender and point of health service showed no significant difference in gene mutation (Table 4).

Table 4. Distribution of rifampicin resistance and participants' characteristics (N=56,004))

Variable	Total participants	# Total RR	Proportion	P value
Age Group				
<15	1765	6	0.34	
15-59	45782	383	0.84	
>59	8457	61	0.72	0.047
Gender				
Male	38705	312	0.81	
Female	17299	138	0.80	0.918
TB Type				
Pulmonary	55192	438	0.79	
Extra pulmonary	550	5	0.91	
Pulmonary and extra pulmonary	262	7	2.67	0.003
Treatment History				
New patient	53818	334	0.62	
Previous treated	2186	116	5.31	< 0.001
HIV status				
Positive	10601	134	1.26	
Negative	45016	306	0.68	< 0.001
Referral type				
Community	46897	364	0.78	
Health facility	6167	60	0.97	
Others	2940	26	0.88	0.234

^{**} The frequency for HIV status is less due to unknown status.

Predictors of rifampicin resistance

158

159

160

161

162

163

164

165

166

167

Compared to pulmonary TB, patients with both pulmonary and extra-pulmonary TB had about four times greater odds of developing rifampicin resistance (AOR 3.88, 95%CI: 1.80 - 8.32). The likelihood of rifampicin resistance was nearly nine times higher in previously treated patients compared to new (AOR 8.66, 95%CI: 6.97 - 10.76). HIV-positive individuals had nearly twice the odds of developing rifampicin resistance than HIV-negative individuals (AOR 1.91, 95%CI: 1.51 - 2.42) (Table 5).

Table 5. Multivariate Logistic regression analysis for the predictors of Rifampicin resistance

Characteristic	Rif. resistance	COR (95% CI)	P-value	AOR (95% CI)	P-
	n (%)				value
Age Group					
<15	6 (0.34)	Ref		Ref	
15-59	383 (0.84)	2.47(1.10 - 5.55)	0.028	2.07(0.92 - 4.67)	0.078
>59	61 (0.72)	2.13(0.92 - 4.93)	0.078	1.95 (0.84 - 4.54)	0.119
TB Type					
Pulmonary	438 (0.79)	Ref		Ref	
Extra pulmonary	5 (0.91)	1.15(0.47 - 2.78)	0.762	1.19(0.49 - 2.92)	0.694
Pulmonary and extra pulmonary	7 (2.67)	3.43 (1.61 -7.31)	0.001	3.88 (1.80 – 8.32)	0.001
Treatment History					
New patient	334 (0.62)	Ref		Ref	
Previous treated	116 (5.31)	8.97 (7.23 – 11.13)	< 0.001	8.66 (6.97 – 10.76)	< 0.001
HIV status					
Negative	306 (1.26)	Ref		Ref	
Positive	134 (0.68)	1.87 (1.53 - 2.29)	< 0.001	1.82 (1.44 – 2.30)	< 0.001
Referral type					
Community	364 (0.78)	Ref		Ref	
Health facility	60 (0. 97)	1.25 (0.95 – 1.65)	0.104	0.83 (0.61 - 1.14)	0.250
Others	26 (0.88)	1.14 (0.76 – 1.70)	0519	0.99 (0.66 – 1.48)	0.969

169 Discussion

The current study found that the most prevalent mutation in rpoB gene mutation in MTB was at probe E codon (529–533) (40.64%), followed by Probe D codon (523–529) 20.09% which was similar to studies done in Nigeria, Uganda, Pakistan, Addis Ababa Ethiopia, and Bangladesh (13–17), the similarities suggests that a significant number of low-income individuals migrating for shelters may be responsible for the spread of mutant strains within the community (18). Our findings differed from the study done in Northeast India and Enugu, South Eastern Nigeria, which revealed that the most prevalent mutations were detected at probes A and D, respectively (19,20). The differences might be attributed to geographical differences caused by the variations in the *M*.

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

tuberculosis lineage (21). According to the results of our study and previous studies, probe E is linked to the most common probe mutation in the rpoB gene mutation. The study found that new TB patients had a significantly higher number of specific rpoB mutations not detected among those with rifampicin resistance than previously treated patients. Our finding is similar to a Northeast India study (20). This may result from an early stage of TB diagnosis, which may have a low bacillary load. No missing probe may also be triggered by various probes having varying target hybridization dynamics, which might have a higher impact after extended PCR cycles (22). Patients with low TB bacillary load also had more no-missing probes. This could mean GeneXpert testing in patients with less advanced disease and lower bacterial density (new patients) is considered less accurate in detecting rifampicin-resistant tuberculosis (23). The very low bacillary load on GeneXpert testing was shown to be substantially linked to false rifampicin resistance during the initial GeneXpert assay (22). The samples with very low bacillary load were not retested; hence, the rate of false positives for rifampicin resistance could not be determined. The rifampicin resistance was found more in patients with both pulmonary and extra-pulmonary TB than in pulmonary or extra-pulmonary alone. In addition, patients with both pulmonary and extra-pulmonary TB had almost four times greater odds of developing rifampicin resistance. Our findings were comparable to the study done in the Debre Markos Referral Hospital Ethiopia (24). We also found that previously treated patients had significantly higher rifampicin resistance than new patients. The likelihood of rifampicin resistance was nearly nine times higher in previously treated patients than in new patients, similar to the study done in Nepal (25). Our findings support that MTB increases the ability to develop resistance when exposed to anti-TB drugs, especially in patients with poor adherence to treatment (26). In our study, the odds of developing rifampicin

resistance in previously treated patients were higher than in Somalia and other East Gojjam zone northwest Ethiopia studies, which revealed four and six times, respectively (27,28). HIV-positive TB patients had a higher gene mutation than HIV-negative. HIV-positive individuals had nearly twice the odds of developing rifampicin resistance than HIV-negative individuals; this was similar to the studies done in northwest Ethiopia (27,29). Variations in TB/HIV co-infection have been reported in several studies, indicating challenges in diagnosis and treatment due to unusual clinical presentations and difficulties in diagnosis and treatment (30–32). This may be due to differences in TB control strategies and approaches (29). More rifampicin-resistant MTB in HIV patients might be caused by poor treatment adherence. Poor adherence to treatment is the primary factor contributing to drug resistance (25,31). This highlights the need for more surveillance and community involvement. The study had limitations, including missing variables and being unable to confirm false positive rates for rifampicin resistance at low bacillary load. However, the large sample size of participants from all Tanzania mainland regions made the findings representative and generalisable to all regions. **Conclusion**

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

The rate of rifampicin resistance in our study was low compared to other studies done in Tanzania. The Probe E (codons 529–533)-related mutations were the most prevalent rpoB gene mutation. Patients with disseminated TB, HIV co-infection and those with prior exposure to anti-TB are associated with rifampicin resistance. The findings highlight the need to strengthen the surveillance of MDR-TB among patients identified with a higher risk of rifampicin resistance.

Ethical considerations

- 222 Ethical approval was obtained from the MUHAS Senate Research and Publications Committee of
- Muhimbili University of Health and Allied Sciences, Ref. No. DA.282/298/01L/629. Approval to
- use the national TB program data was obtained from the NTLP Program Manager in the Ministry
- of Health (MoH). The data was routinely collected by health facilities providing TB care and
- treatment services in which ethical issues are strongly advocated.

Author contributions

- PRT, AJ, HK, MVM and LU authors contributed equally to the design. PRT, MRM, MCM, SSN,
- 229 RMK, CF, RB, PS and JK did data collection and write-up of this manuscript. AJ and MVM
- reviewed the manuscript. All authors read and approved the final manuscript.

Acknowledgments

- We are very grateful to the Muhimbili University of Health and Allied Sciences, Ministry of Health,
- NTLP program, Tanzania Field Epidemiology and Laboratory program for technical support of this
- 234 study.

221

227

231

235

References

- 1. Global Tuberculosis report 2022. 2022. Available from: http://apps.who.int/bookorders...
- 237 2. Yan Shao, Dandan Yang, Weiguo Xu, Wei Lu, Honghuan Song, Yaoyao Dai, Hongbing
- Shen & Jianming Wang. Epidemiology of anti-tuberculosis drug resistance in a chinese
- population: Current situation and challenges ahead. BMC Public Health. 2011;11.
- 240 https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-11-110#Abs1

- 3. Molla KA, Reta MA, Ayene YY. Prevalence of multidrug-resistant tuberculosis in East
- Africa: A systematic review and meta-analysis. PLoS One. 2022 Jun 1;17(6 June). https://
- 243 <u>doi: 10.1371/journal.pone.0270272.</u>
- 4. Tuberculosis: Multidrug-resistant tuberculosis (MDR-TB). https://www.who.int/news-
- room/questions-and-answers/item/tuberculosis-multidrug-resistant-tuberculosis-(mdr-tb)
- World Health Organization. The End Strategy TB. End TB Strateg. 2015;53(9):1689–99.
- https://www.who.int/publications-detail-redirect/WHO-HTM-TB-2015.19
- World Health Organization (WHO). WHO operational handbook on tuberculosis. Module 3:
- 249 Diagnosis Rapid diagnostics for tuberculosis detection 2021 update
- 250 https://apps.who.int/iris/bitstream/handle/10665/340256/9789240022614-eng.pdf
- 251 7. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, et al. Rapid detection of
- Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient
- technology. J Clin Microbiol. 2010;48(1):229–37. https://doi: 10.1128/JCM.01463-09. Epub
- 254 2009 Oct 28.
- Unit MR, Health P, Hospital D, Grove ED. The rapid diagnosis of isoniazid and rifampicin
- resistance in. 1998;47:189–96. J Med Microbiol. 1998 Mar;47(3):189-96.
- 257 https://doi:10.1099/00222615-47-3-189.
- 258 9. Tao N. Risk factors for drug- resistant tuberculosis, the association between resistant
- comorbidity status and drug- patterns: a retrospective study of previously treated
- pulmonary tuberculosis in Shandong, China, during 2004 2019. 2021;1–9. http://doi:
- 261 <u>10.1136/bmjopen-2020-044349.</u>

- 262 10. Akalu GT, Tessema B, Petros B. High proportion of RR-TB and mutations conferring RR
- outside of the RRDR of the rpoB gene detected in GeneXpert MTB/RIF assay positive
- pulmonary tuberculosis cases, in Addis Ababa, Ethiopia. PLoS One. 2022;17(12)
- 265 December):1–18. http://dx.doi.org/10.1371/journal.pone.0277145
- 266 11. Reta MA, Alemnew B, Abate BB, Fourie PB. Prevalence of drug resistance-conferring
- mutations associated with isoniazid- and rifampicin-resistant Mycobacterium tuberculosis in
- Ethiopia: a systematic review and meta-analysis. J Glob Antimicrob Resist. 2021;26:207–
- 269 18. https://doi.org/10.1016/j.jgar.2021.06.009
- 270 12. Lavu EK, Johnson K, Banamu J, Pandey S, Carter R, Coulter C, et al. Drug-resistant
- 271 tuberculosis diagnosis since Xpert ® MTB/RIF introduction in Papua New Guinea, 2012–
- 272 2017 . Public Heal Action. 2019;9(1):S12–8. https://doi:10.5588/pha.19.0005.
- 273 13. Mboowa G, Namaganda C, Ssengooba W. Rifampicin resistance mutations in the 81 bp
- 274 RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert® MTB/RIF
- in Kampala, Uganda: A retrospective study. BMC Infect Dis. 2014 Sep 4;14(1):1–5.
- https://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-14-481
- 277 14. Ullah I, Shah AA, Basit A, Ali M, khan A, Ullah U, et al. Rifampicin resistance mutations in
- 278 the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert
- MTB/RIF in Khyber Pakhtunkhwa, Pakistan: A retrospective study. BMC Infect Dis.
- 280 2016;16(1):4–9. http://dx.doi.org/10.1186/s12879-016-1745-2
- 281 15. Alemu A, Tadesse M, Seid G, Mollalign H, Eshetu K, Sinshaw W, et al. Does Xpert®
- MTB/RIF assay give rifampicin resistance results without identified mutation? Review of
- cases from Addis Ababa, Ethiopia. BMC Infect Dis. 2020;20(1):1–6. https://doi:


10.1186/s12879-020-4817-2

284


- 16. Uddin MKM, Rahman A, Ather MF, Ahmed T, Rahman SMM, Ahmed S, et al. Distribution 285 286 and frequency of rpob mutations detected by xpert MTB/RIF assay among beijing and non-287 beijing rifampicin resistant Mycobacterium tuberculosis isolates in Bangladesh. Infect Drug Resist. 2020;13:789–97. https://www.dovepress.com/infection-and-drug-resistance-journal 288 17. Ochang EA, Udoh UA, Emanghe UE, Tiku GO, Offor JB, Odo M, et al. Evaluation of 289 rifampicin resistance and 81-bp rifampicin resistant determinant region of rpoB gene 290 291 mutations of Mycobacterium tuberculosis detected with XpertMTB/Rif in Cross River State, J Mycobacteriology. Nigeria. Int 2016;5:S145-6. 292 http://dx.doi.org/10.1016/j.ijmyco.2016.09.007 293 294 18. Adhikari S, Saud B, Sunar S, Ghimire S, Yadav BP. Status of rpoB gene mutation associated with rifampicin-resistant Mycobacterium tuberculosis isolated in a rural setting in Nepal. 295 Access Microbiol. 2021;3(3):10–3. https://DOI: 10.1099/acmi.0.000202 296 Ugwu KO, Onah IS, Mbah GC, Ezeonu IM. Rifampicin resistance patterns and dynamics of 19. 297 tuberculosis and drug-resistant tuberculosis in Enugu, South Eastern Nigeria. J Infect Dev 298 Ctries. 2020;14(9):1011–8. https://doi:10.3855/jidc.12736. 299 Sailo CV, Lalremruata R, Sanga Z, Fela V, Kharkongor F, Chhakchhuak Z, et al. Distribution 20. 300 301 and frequency of common mutations in rpoB gene of Mycobacterium tuberculosis detected by Xpert MTB/RIF and identification of residential areas of rifampicin resistant-TB cases: J 302 Clin Tuberc Other Mycobact Dis. https://doi.org/10.1016/j.jctube.2022.100342 303
- 21. Ektefaie Y, Dixit A, Freschi L, Farhat MR. Globally diverse Mycobacterium tuberculosis resistance acquisition: a retrospective geographical and temporal analysis of whole genome

sequences. The Lancet Microbe. 2021;2(3):e96-104. http://dx.doi.org/10.1016/S2666-306 5247(20)30195-6 307 Ngabonziza JCS, Decroo T, Migambi P, Habimana YM, Van Deun A, Meehan CJ, et al. 308 22. Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a 309 prospective observational study in Rwanda. The Lancet Microbe [Internet]. 2020;1(2):e74-310 311 83. http://dx.doi.org/10.1016/S2666-5247(20)30007-0 23. Variava E, Moloantoa T, Martinson NA. Discrepancies in Xpert tuberculosis testing. The 312 [Internet]. 313 Lancet Microbe 2020 Jun [cited 2023 Nov 30]:1(2):e47–8. 314 http://www.thelancet.com/article/S2666524720300331/fulltext Mulu W, Abera B, Yimer M, Hailu T, Ayele H, Abate D. Rifampicin-resistance pattern of 315 24. 316 Mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients referred to Debre Markos Referral Hospital, Ethiopia: a cross-sectional study. BMC Res 317 Notes. 2017;10(1):1–8. https://doi.org/10.1186/s12879-019-3943-1 318 319 25. Sah SK, Bhattarai PR, Shrestha A, Dhami D, Guruwacharya D, Shrestha R, Rifampicinresistant mycobacterium tuberculosis by genexpert mtb/rif and associated factors among 320 presumptive pulmonary tuberculosis patients in nepal. Infect Drug Resist. 2020;13:2911–9. 321 https://www.dovepress.com/infection-and-drug-resistance-journal 322 Berhan A, Berhan Y, Yizengaw D. A meta-analysis of drug resistant tuberculosis in Sub-323 26. 324 Saharan Africa: how strongly associated with previous treatment and HIV co-infection? 325 Ethiop J Health Sci. 2013;23(3):271–82. https://doi:10.4314/ejhs.v23i3.10. 326 27. Adane K, Ameni G, Bekele S, Abebe M, Aseffa A. Prevalence and drug resistance profile of Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients attending two 327

public hospitals in East Gojjam zone, northwest Ethiopia Infectious Disease epidemiology. 328 BMC Public Health. 2015;15(1):1–8. https://doi:10.1186/s12889-015-1933-9 329 28. Ali MM, Weldegebreal F, Kabew G, Urgesa K. Rifampicin resistant Mycobacterium 330 331 tuberculosis and associated factors among presumptive pulmonary tuberculosis patients in Mogadishu, Somalia. SAGE Open Med. 2023;11. https://doi:10.1177/20503121221148603 332 29. Ayalew ML, Yigzaw WB, Tigabu A, Tarekegn BG. Prevalence, associated risk factors 333 rifampicin resistance pattern of pulmonary tuberculosis among children at debre markos 334 335 referral hospital. Northwest. Ethiopia. Infect Drug Resist. 2020;13:3863–72. https://DOI:10.2147/IDR.S277222 336 337 30. Yitayew YA, Bekele DM, Wondimeneh B, Menji DZA. Mother to child transmission of HIV and associated factors among HIV exposed infants at public health facilities, Dessie town, 338 Ethiopia. HIV/AIDS - Res Palliat Care. 2019;11:343–50. https://doi:10.2147/HIV.S221409 339 340 31. Diriba K, Awulachew E, Churiso G. The magnitude of mtb and rifampicin resistance mtb using xpert-mtb/rif assay among tuberculosis suspected patients in gedeo zone, southern 341 ethiopia. Infect Resist. 2021;14:3961-9. 342 Drug https://doi:10.2147/IDR.S327607.eCollection2021 343 Jaganath D, Zalwango S, Okware B, Nsereko M, Kisingo H, Malone LS, et al. Contact 32. 344 345 investigation for active tuberculosis among child contacts in Uganda. Clin Infect Dis. 2013;57(12):1685–92: https://doi:10.1093/cid/cit645 346



Figure



Figure